Omega Funds led a $120m Series B round in Ikena Oncology, a clinical-stage biotechnology company, with participation from Fidelity Management & Research Company, Surveyor Capital, Invus, Farallon Capital Management, BVF Partners, Cowen Healthcare Investments, Logos Capital, HealthCor Management, Atlas Venture, OrbiMed and Bristol Myers Squibb. "This exceptional group of new investors is a welcome addition to our strong existing group of shareholders as we continue to advance and build Ikena’s portfolio of targeted oncology programs for a wide range of cancer types," Mark Manfredi, Ikena Oncology, President and CEO.